Abstracts Archive - Page 128 of 2607 - ACR Meeting Abstracts

Abstract Number: 1818 • ACR Convergence 2025
Epigenetic Profiling of Childhood-onset Lupus Reveals Distinct Epigenetic Clusters and Suggests Epigenetic Drivers of Disease Activity
Desire Casares Marfil¹, Gülşah Kavrul Kayaalp², Vafa Guliyeva², Özlem Akgün², Şeyma Türkmen³, Elif Kilic Konte⁴, Seher Şener⁵, Sezgin Sahin⁴, Ozgur Kasapcopur⁶, Betul Sozeri⁷, Selçuk Sözer Tokdemir⁸, Seza Özen⁹, Nuray Aktay Ayaz² and Amr Sawalha¹, ¹University of Pittsburgh, Pittsburgh, PA, ²Istanbul University Faculty of Medicine, Istanbul, Turkey, ³University of Health Sciences, Umraniye Research and Training Hospital, Istanbul, Turkey, ⁴Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, ⁵Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Istanbul University-Cerrahpasa, Cerrahpasa Medical School, istanbul, Turkey, ⁷Health sciences university, Istanbul, Turkey, ⁸Istanbul University, Istanbul, Turkey, ⁹Hacettepe University Medical Faculty, Ankara, Turkey
Background/Purpose: Childhood-onset lupus is generally associated with a more severe disease course than adult-onset lupus. DNA methylation alterations are known to play a key role…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…
Abstract Number: 1781 • ACR Convergence 2025
Specific gut microbiome remodeling occurs after induction of OA via DMM surgery compared to sham surgery
Aleksander Szymczak¹, Cindy Miranda Brawner², Nicholas Hanebutt², Gabriella Dyson², Montana Barrett², Anna Rapp³, Carla Scanzello⁴ and Matlock Jeffries¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³University of Pennsylavnia, Philadelphia, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: The destabilization of the medial meniscus (DMM) model is widely used in murine OA research due to its reproducibility and ability to recapitulate key…
Abstract Number: 1778 • ACR Convergence 2025
Towards an Earlier and Accurate Diagnosis of Connective Tissue Disease-related Interstitial Lung Disease: TGFB Isoform Genes as Upcoming Biomarkers
Verónica Pulito Cueto¹, Joao Carlos Batista-Liz¹, Rebeca Nieto-Nieto², Clara Vaquera-Illescas², Diego San Emeterio-Villar², Daniel Vicente-Mínguez², María Sebastián Mora-Gil², Belén Atienza-mateo³, Ana Serrano-Combarro⁴, David Iturbe-Fernández⁵, Victor M. Mora-Cuesta⁵, Carolina Aguirre-Portilla⁴, Jose M Cifrián⁵, Ricardo Blanco⁴ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, PALMA DE MALLORCA/BALEARES, Spain, ⁴Immunopathology Group, IDIVAL and Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the leading cause of mortality in patients with connective tissue diseases (CTDs) [1]. The onset of CTD-ILD…
Abstract Number: 1838 • ACR Convergence 2025
Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Lars Van Vliet, Annemarie Dorjée, René Toes and Jolien Suurmond, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-dsDNA IgG antibodies are a hallmark of systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic inflammation and multi-organ damage. Evidence suggests that…
Abstract Number: 1588 • ACR Convergence 2025
Prevalence Of Oral Manifestations And Their Association With Clinical And Serological Profile In Systemic Sclerosis Patients- An Indian Study
Vijaya prasanna Parimi¹, Tejaswini Ramineni², Pradeep S Anand³, Vineeta Shobha⁴, Padmanabha Shenoy⁵, Geetabali Sircar⁶, kaushik Basu⁷, Anna C Das⁴, Geetha Amritrao Kale⁴, indranil sarkar⁸, Shinie Razil Goveas⁴, Biswarup Sengupta⁸, Caseena Kareem⁹, Yogananth Sakthivel⁴, Soma Halder Biswas⁷ and Neel Nallulwar⁸, ¹ESIC Medical College and Super Specilaity Hospital, hyderabad, Telangana, India, ²Esic Medical College And Hospital, Sanathnagar, Hyderabad, Telangana, India, ³ESIC MEDICAL COLLEGE AND HOSPITAL, HYDERABAD, Telangana, India, ⁴St. John's Medical College Hospital, Bangalore, Bangalore, Karnataka, India, ⁵Shenoy's CARE, Kochi, Kerala, India, ⁶West Bengal Medical Education Service, Kolkata, West Bengal, India, ⁷Medical College, Kolkata, kolkata, West Bengal, India, ⁸IPGMER, Kolkata, kolkata, West Bengal, India, ⁹CARE, Kochi, kochi, Kerala, India
Background/Purpose: Systemic sclerosis (SSC) is a chronic, multisystem autoimmune disease characterized by immune dysfunction, microangiopathy, and tissue remodelling. Orofacial manifestations, including xerostomia, microstomia, tooth decay,…
Abstract Number: 1833 • ACR Convergence 2025
DM618: A Novel Anti-IL12p35 Antibody Specifically Inhibiting IL-12 with Therapeutic Potential in a Set of Autoimmune Diseases
Dong ZHANG, Guangan Hu, Xiaodong Jiang, Quanju Zhao, Tainfei Hou, Zhengwang Sun, Mousheng Xu and Nan Bing, D²M Biotherapeutic, Inc, NATICK, MA
Background/Purpose: IL-12, via its p35 subunit, drives Th1-mediated pathology in autoimmune diseases. Genome-wide association studies (GWAS) suggested that IL12A encoding IL12p35 is associated with systemic…
Abstract Number: 1876 • ACR Convergence 2025
Targeting the NK cell checkpoint NKG2A promotes lung fibrosis resolution by enhancing immune clearance of senescent myofibroblasts
Wolfgang Merkt¹, Lea Rodon², Franca Sophie Deicher³, Maren Claus⁴, Rachel Lister⁵, Hongwei Han⁵, Yan Zhou⁵, Zhengwang Sun⁵, Arik Horne⁶, Ayla Nadja Stuetz⁷, Michael Kreuter⁸, nicolas kahn⁹, Marc Schneider⁹, Simon Haas¹⁰, Norbert Blank¹¹, Hanns-Martin Lorenz¹², Carsten Watzl⁴, Daniel Hübschmann¹³ and David Lagares⁵, ¹University Hospital Düsseldorf, Düsseldorf, Germany, ²University Hospital Heidelberg, Heidelberg, Hungary, ³Uniklinik Düsseldorf, Düsseldorf, Germany, ⁴IfADo, Leibniz Institute Dortmund, Dortmund, Germany, ⁵Massachusetts General Hospital and Harvard Medical School, Boston, ⁶Charite, Berlin, Berlin, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ⁸Universitätsmedizin Mainz, Mainz, ⁹Thoraxklinik, Heidelberg University, Heidelberg, Germany, ¹⁰Charite, Berlin, Berlin, Germany, ¹¹University Hospital Heidelberg, Heidelberg, Germany, ¹²Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹³Heidelberg University, Berlin, Germany
Background/Purpose: A key event driving pulmonary fibrosis in interstitial lung disease (ILD) is the accumulation of pathologic senescent myofibroblasts, thought to be promoted by insufficient…
Abstract Number: 1753 • ACR Convergence 2025
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Christopher Ritchlin¹, Javier Rangel-Moreno², Angel Rangel-Garcia³, Marissa Krantz⁴, Madison Brien², Thiloginy Sathilaseenlan², Jeffrey Fox⁵, Ronald Wood² and Maria de la Luz Garcia-Hernandez³, ¹University of Rochester Medical Center, Canandaigua, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, West Henrietta, NY, ⁴University of Rochester, Bethesda, MD, ⁵University od Rochester, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic…
Abstract Number: 1718 • ACR Convergence 2025
Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus
Kevin Sheng-Kai Ma¹, Dominique Feterman Jimenez², You Wu³, Jenna Thomason³, Jean Liew⁴ and Namrata Singh⁵, ¹Center for Global Health, Perelman School of Medicine, Philadelphia, PA, ²University of Washington, Seattle, ³University of Washington, Seattle, WA, ⁴Boston University, Boston, MA, ⁵University of Washington, Bellevue, WA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, but their safety profile in patients with pre-existing autoimmune diseases, such as systemic lupus erythematosus (SLE),…
Abstract Number: 1732 • ACR Convergence 2025
Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis
Takemichi Matsui¹, Kenji Yamada², Toshiaki Takahashi³, Yoshito Nishimura⁴ and Yu Fujiwara⁵, ¹Department of Medicine, Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Kameda Medical Center, Chiba, Japan, ³Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, ⁴Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, ⁵Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have become essential in cancer treatment, offering significant survival benefits across various malignancies. However, ICIs can cause immune-related Adverse Events…
Abstract Number: 1537 • ACR Convergence 2025
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Soraya Kharboutli³, Silvia Spoerl³, Christina Duesing⁴, Tobias Krickau⁵, Markus Metzler⁵, Simon Völkl³, Michael Aigner³, Sascha Kretschmann³, Ingrid Vasova³, Marc Saake⁵, Stefan Schliep⁵, Torsten Kubacki⁶, Nicolas Hunzelmann⁶, Laura Bucci¹, Jule Taubmann⁷, Christina Bergmann¹, Andrea-Hermina Györfi⁸, Sascha Dietrich⁹, Jörg Distler¹⁰, Ricardo Grieshaber-Bouyer¹¹, Andreas Mackensen¹² and Georg Schett¹³, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²University Hospital of Erlangen, Erlangen, Germany, ³Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Klinik für Rheumatologie, Düsseldorf, Germany, ⁵Friedrich-Alexander-Universität Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶University and University Hospital Cologne, Cologne, Germany, Cologne, Germany, ⁷Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁹Heinrich Heine University Duesseldorf, University Hospital Duesseldorf, Duesseldorf, Germany, ¹⁰University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹¹University Hospital Erlangen, Erlangen, Germany, ¹²Department of Medicine ⁵ - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ¹³Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment strategies for severe B-cell driven autoimmune diseases (AID) like Systemic Lupus erythematosus (SLE), Systemic…
Abstract Number: 1839 • ACR Convergence 2025
Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways
Christopher Sisk¹, Loqmane Seridi², Alan Perlman³, Matthew Loza², Sheng Gao², Thomas Parker⁴, Daniel Levine⁴, Thangamani Muthukumar⁵, Yonatan Bardash⁶, Benjamin Horowitz⁷, Surya Seshan⁵ and James Chevalier³, ¹Johnson & Johnson, San Diego, CA, USA, San Diego, CA, CA, ²Johnson & Johnson, Spring House, PA, ³The Rogosin Institute, New York, NY, ⁴The Rogosin Institute, Weill Cornell Medical College, New York, NY, ⁵Weill Cornell Medical College, New York, NY, ⁶Hackensack Meridian Health, Hackensack, NJ, ⁷Columbia University Medical Center, New York, NY
Background/Purpose: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE), associated with significant morbidity and mortality. IgA nephropathy (IgAN) is the most…
Abstract Number: 1877 • ACR Convergence 2025
Demographics and trends of Inflammatory Arthritis-Related Mortality in the United States, 1999–2019
Aishwarya Sudheer¹, Ishan Jani², Sarath Lal Mannumbeth Renjithlal² and Qi Wang³, ¹Saint Vincent Hospital, Worcester, MA, ²Rochester General Hospital, Rochester, NY, ³Metrohealth System/Case Western Reserve University, Cleveland, OH
Background/Purpose: The study aims to evaluate the racial, sex-related and urbanization-related trends of deaths in patients with inflammatory polyarthropathies in the United States between 1999…
Abstract Number: 1790 • ACR Convergence 2025
Targeted Ablation of Knee-innervating Nociceptors Attenuates Pain and Cartilage Degeneration in Experimental Osteoarthritis
Lai Wang¹, alia obeidat², Shingo Ishihara³, Jun Li², Frank Ko², Terese Geraghty², Natalie Adamczyk³, Sarah Soorya², Richard Miller⁴, Rachel Miller¹ and Anne-Marie Malfait², ¹Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, ³Rush University, Chicago, ⁴Northwestern University, Chicago
Background/Purpose: Nociceptors abundantly innervate the knee joint. In experimental osteoarthritis (OA), nociceptors sprout in the medial synovium and in subchondral bone channels. We aimed to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].